.jpeg)
Where to buy Necitumumab
Nexituzumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer. Nexituzumab exhibits dose-dependent kinetics. When nesituzumab 800 mg is administered on days 1 and 8 of each 21-day cycle, the elimination half-life is approximately 14 days at steady state. The estimated time to reach steady state is approximately 100 days. The patent drug Nexituzumab has not yet been approved for marketing in China, so it has not been included in medical insurance. Domestic patients may not be able to purchase this drug yet. The German version of the generic version of Nexituzumab 800mg/50ml listed overseas may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. For more drug information and specific prices, please consult Yaode’s medical consultant.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
